HOME >> MEDICINE >> NEWS
Sharing clinical trial results with participants may be beneficial

Offering patients the results of clinical trials that they have participated in could have a positive effect, suggests a study published in his week's issue of THE LANCET.

Clinical research trials designed to improve healthcare depend on the voluntary participation of patients. However, patients are not routinely given information about the aggregate results of trials in which they have participated, unless it affects their future care. The limited information available on this issue suggests that many patients would be interested in learning such results.

Ann Partridge (Dana-Faber Cancer Institute, MA, USA) and colleagues offered results to 135 participants in a cancer trial of breast excision alone for women with ductal carcinoma in situ. The study was stopped early because of a high rate of local recurrence. 85 (90%) of the 94 participants who responded chose to receive results; these women were more educated than those who chose not to. 68 (80%) patients received results by mail, 27 (32%) in person, two (2%) by telephone and two (2%) by other methods. Of the 68 patients who received results by mail, 63 (93%) were comfortable with this method. Respondents were asked if they were more anxious about the possibility of breast cancer in the future after being offered results, seven (7%) were much more concerned, ten (11%) somewhat more concerned, 29 (31%) a little more concerned, 44 (47%) were neither less or more concerned.

Despite the increased anxiety experienced by some participants, 90 (96%) of the 94 respondents were glad to have been offered the results, and 83 (88%) would want to be informed of overall results if they were to participate in other studies. 81 (95%) of the 85 respondents who learned results did not regret their decision, 13 (15%) felt the information had had an important effect on their lives. 88 (94%) believed they had been treated with dignity and respect; and 66 (70%) would recommend participation in a clinical tri
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
10-Mar-2005


Page: 1 2

Related medicine news :

1. UCSF Study Shows Novel "Stress-Sharing" Prosthetic Device To Save Legs With Cancer Stimulates Bone Development
2. British hospitals need clinical ethicists
3. Lack of clinical trial participation may contribute to lower survival rates
4. Obtaining patient consent for clinical audit is unworkable without extra resources
5. Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit
6. PENN begins clinical trial of newest technology to treat thoracic aortic aneurysms
7. Most episodes of HIV blips not clinically significant in patients receiving HAART
8. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
9. New non-hormonal hot flash treatment set for clinical trial
10. Study naming hospitals in top 5% for clinical quality released by HealthGrades
11. Future of clinical medicine research is at risk, warns professor

Post Your Comments:
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
Cached News: